|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1270475963 |
| 003 |
OCoLC |
| 005 |
20231120010606.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
210930s2022 enka o 001 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d OCLCO
|d OCLCF
|d OCLCO
|d OCLCQ
|d OCLCO
|d K6U
|d SFB
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|z 9780128219850
|
| 020 |
|
|
|z 0128219858
|
| 035 |
|
|
|a (OCoLC)1270475963
|
| 050 |
|
4 |
|a RA1224.2
|
| 082 |
0 |
4 |
|a 616.4
|2 23
|
| 245 |
0 |
0 |
|a Endocrine disruption and human health /
|c edited by Philippa D. Darbre.
|
| 250 |
|
|
|a Second edition.
|
| 264 |
|
1 |
|a London, United Kingdom :
|b Academic Press,
|c [2022]
|
| 300 |
|
|
|a 1 online resource (1 volume) :
|b color illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front Cover -- ENDOCRINE DISRUPTION AND HUMAN HEALTH -- ENDOCRINE DISRUPTION AND HUMAN HEALTH -- Copyright -- Contents -- Contributors -- Preface -- 1 -- Overview and scope -- 1 -- What Are Endocrine Disrupters and Where Are They Found? -- 1.1 INTRODUCTION -- 1.2 HISTORICAL BACKGROUND -- 1.3 EVIDENCE FOR ENDOCRINE DISRUPTION IN WILDLIFE POPULATIONS AND HOW THIS MAY PREDICT EFFECTS ON HUMAN HEALTH -- 1.3.1 TBT and Imposex in Mollusks -- 1.3.2 Dicofol and Reproduction of Alligators -- 1.3.3 Feminization of Male Fish in the UK Rivers -- 1.3.4 Eggshell Thinning in Birds -- 1.4 WHICH HORMONES ARE DISRUPTED BY EDCS? -- 1.5 HOW DO EDCS DISRUPT HORMONE ACTION? -- 1.6 WHICH CHEMICALS ARE SOURCES OF HUMAN EXPOSURE TO ENDOCRINE DISRUPTERS? -- 1.6.1 Persistent Organic Pollutants-"The Dirty Dozen" -- 1.6.2 Other Persistent Organic Pollutants -- 1.6.3 Herbicides-Atrazine and Glyphosate -- 1.6.4 Bisphenol A -- 1.6.5 Phthalates -- 1.6.6 Alkylphenols -- 1.6.7 Triclosan -- 1.6.8 Parabens -- 1.6.9 UV Filters -- 1.6.10 Organometals and Metals -- 1.6.11 Other EDCs in Personal Care Products -- 1.6.12 Pharmaceuticals -- 1.6.13 Mycoestrogens -- 1.6.14 Phytoestrogens -- 1.6.15 Nutraceuticals -- 1.7 CONCLUDING COMMENTS -- References -- 2 -- How Could Endocrine Disrupters Affect Human Health? -- 2.1 INTRODUCTION -- 2.2 ROUTES OF ENTRY INTO HUMAN TISSUES -- 2.3 TISSUE MEASUREMENTS -- 2.3.1 Biomarkers -- 2.4 ROLE OF METABOLISM IN BIOLOGICAL ACTIVITY OF EDCS -- 2.4.1 Metabolism May Alter the Endocrine-Disrupting Properties of an EDC -- 2.4.2 EDCs May Alter Endogenous Enzyme Activities -- 2.5 BIOLOGICAL AVAILABILITY -- 2.5.1 Binding to Serum Proteins -- 2.5.2 Modification by Conjugation -- 2.6 DOSE-RESPONSE CONSIDERATIONS -- 2.6.1 Receptor Binding Affinity Versus Response Efficacy -- 2.6.2 Effect of Length of Exposure Time on End-Point Response.
|
| 505 |
8 |
|
|a 2.7 EFFECT OF EXPOSURE TO MIXTURES OF CHEMICALS -- 2.8 IMPORTANCE OF TIMING OF EDC EXPOSURE -- 2.8.1 Critical Windows of Susceptibility During Development -- 2.8.2 Latency Periods -- 2.8.3 Disruption to Normal Cyclical Hormonal Patterns -- 2.8.4 Reversibility of Endocrine Disruption -- 2.9 MULTIGENERATIONAL AND TRANSGENERATIONAL TRANSMISSION AND EPIGENETIC MECHANISMS -- 2.10 EDCS DO NOT HAVE THE SAME EFFECT IN ALL TISSUES -- 2.11 EDCS CAN CHANGE THE MICROENVIRONMENT WITHIN A TISSUE -- 2.12 EDCS DO NOT HAVE THE SAME EFFECTS IN EVERY INDIVIDUAL: THE INTERACTION OF GENETICS WITH ENVIRONMENT -- 2.13 CONCLUDING COMMENTS -- References -- 2 -- Mechanisms and assay systems -- 3 -- Disrupters of Estrogen Action and Synthesis -- 3.1 PHYSIOLOGICAL ACTIONS OF ESTROGEN AND IMPLICATIONS OF DISRUPTION -- 3.2 MOLECULAR ACTIONS OF ESTROGEN AND MECHANISMS OF DISRUPTION -- 3.2.1 Direct Genomic Action -- 3.2.2 Indirect Genomic Action -- 3.2.3 Nongenomic Action -- 3.2.4 Epigenetic Action -- 3.3 SYNTHESIS OF ENDOGENOUS ESTROGENS AND DISRUPTION OF NECESSARY ENZYMATIC ACTIVITIES -- 3.4 ASSAY SYSTEMS -- 3.4.1 Can a Compound Bind to ER? ER-Binding Assays in a Cell-Free System -- 3.4.2 Can Binding of a Compound to ER Regulate Estrogen-Responsive Gene Expression in Cells In Vitro? -- 3.4.2.1 Reporter Gene Assays -- 3.4.2.2 Endogenous Gene Assays -- 3.4.3 Can Binding of the Compound to ER Increase Proliferation of Estrogen Responsive Cells In Vitro? -- 3.4.4 Can the Compound Increase Uterine Weight in the Immature Rodent In Vivo? -- 3.4.5 Can the Compound Interfere With Biosynthesis of Estrogens? -- 3.4.6 Can the Compound Interfere With Bioavailability of Estrogens? -- 3.5 ENVIRONMENTAL ESTROGENS -- 3.6 CONCLUDING COMMENTS -- References -- 4 -- Disruptors of Androgen Action and Synthesis -- 4.1 PHYSIOLOGICAL ACTIONS OF ANDROGENS -- 4.2 ANDROGEN BIOSYNTHESIS AND METABOLISM.
|
| 505 |
8 |
|
|a 4.3 ANDROGEN RECEPTOR -- 4.3.1 Genomic Mechanisms of Androgen Action -- 4.3.2 Nongenomic Actions of Androgens and the AR -- 4.4 ROLE OF ANDROGENS AND THE AR IN HUMAN DISEASES -- 4.5 ANTIANDROGENS -- 4.6 BIOASSAYS FOR THE EVALUATION OF DISRUPTORS OF ANDROGENIC ACTION -- 4.6.1 In Vivo Bioassays of Androgenic Action -- 4.6.2 In Vitro Bioassays of Androgenic Action -- 4.7 ENVIRONMENTAL DISRUPTORS OF ANDROGENIC ACTION -- References -- 5 -- Disrupters of Thyroid Hormone Action and Synthesis -- 5.1 THE IMPORTANCE OF THE THYROID HORMONAL SYSTEM FOR HUMAN HEALTH -- 5.1.1 Thyroid Hormones and the Hypothalamic-Pituitary-Thyroid Axis -- 5.1.2 The Basic Structure of the Thyroid -- 5.1.3 Thyroid Hormone Synthesis -- 5.1.4 The Molecular Basis of Thyroid Hormone Action -- 5.2 DISRUPTION OF THE THYROID HORMONAL SYSTEM -- 5.2.1 Modes of Action for Thyroid Hormone Disruption -- 5.2.2 Possible Consequences of Thyroid Hormone Disruption -- 5.3 TESTING FOR THYROID HORMONE DISRUPTION -- 5.3.1 In Vivo Assays for Detecting Thyroid Hormone-Disrupting Chemicals -- 5.3.2 In Vitro Assays for Detecting Thyroid Hormone-Disrupting Chemicals -- 5.4 CONCLUSIONS -- References -- 6 -- Disruption of Other Receptor Systems: Progesterone, Glucocorticoid and Mineralocorticoid Receptors, Peroxisome ... -- 6.1 INTRODUCTION -- 6.2 PROGESTERONE RECEPTOR -- 6.2.1 Mechanisms of Action -- 6.2.2 Assay Systems -- 6.3 GLUCOCORTICOID AND MINERALOCORTICOID RECEPTORS -- 6.3.1 Mechanisms of Action -- 6.3.2 Assay Systems -- 6.4 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS -- 6.4.1 Mechanisms of Action -- 6.4.2 Assay Systems -- 6.5 PREGNANE X RECEPTOR AND CONSTITUTIVE ANDROSTANE RECEPTOR -- 6.5.1 Mechanisms of Action -- 6.5.2 Assay Systems -- 6.6 ARYL HYDROCARBON RECEPTOR -- 6.6.1 Mechanisms of Action -- 6.6.2 Assay Systems -- 6.7 PROSTAGLANDINS.
|
| 505 |
8 |
|
|a 6.8 CONCLUDING COMMENTS-HOW MANY OTHER RECEPTORS MAY BE DISRUPTED? -- References -- 7 -- Low Dose Effects and Nonmonotonic Dose Responses for Endocrine Disruptors -- 7.1 INTRODUCTION -- 7.2 DEFINING LOW DOSE EFFECTS -- 7.3 WHAT IS THE EVIDENCE IN SUPPORT OF LOW DOSE EFFECTS? -- 7.4 MECHANISMS FOR LOW DOSE EFFECTS -- 7.5 IMPLICATION OF LOW DOSE EFFECTS -- 7.6 WHAT IS NONMONOTONICITY? -- 7.7 NONMONOTONICITY IN PHARMACOLOGY, ENDOCRINOLOGY, AND NUTRITION -- 7.8 MECHANISMS FOR NONMONOTONICITY -- 7.9 HOW DOES NONMONOTONICITY INFLUENCE CHEMICAL SAFETY ASSESSMENTS? -- 7.10 CONCLUSIONS -- References -- 8 -- Exposure to Mixtures of EDCs and Long-Term Effects -- 8.1 INTRODUCTION -- 8.2 EXPOSURE TO MIXTURES OF EDCS: ADDITIVE EFFECTS OF RECEPTOR-MEDIATED MECHANISMS -- 8.2.1 Estrogen Receptor-Mediated Mechanisms -- 8.2.2 Androgen Receptor-Mediated Mechanisms -- 8.2.3 Thyroid Hormone Receptor-Mediated Mechanisms -- 8.2.4 Peroxisome Proliferator-Activated Receptor Mediated Mechanisms -- 8.2.5 Aryl Hydrocarbon Receptor-Mediated Mechanisms -- 8.3 MIXTURE EFFECTS AT REAL-LIFE TISSUE CONCENTRATIONS -- 8.4 EXPOSURE TO MIXTURES OF EDCS WITH DIFFERENT MECHANISMS OF ACTION -- 8.5 LONG-TERM EXPOSURE TO EDCS -- 8.6 CONCLUDING COMMENTS -- References -- 3 -- Concerns for human health -- 9 -- Endocrine Disruption and Female Reproductive Health -- 9.1 INTRODUCTION -- 9.2 MAJOR TARGETS OF ENDOCRINE DISRUPTION FOR FEMALE REPRODUCTIVE HEALTH -- 9.3 SOURCES OF ENDOCRINE DISRUPTION FOR FEMALE REPRODUCTIVE HEALTH -- 9.4 EXPOSURE TO DES AND CONSEQUENCES FOR FEMALE REPRODUCTIVE HEALTH -- 9.5 PUBERTAL DEVELOPMENT -- 9.5.1 Physiological Changes in Puberty -- 9.5.2 Estrogens in Personal Care Products that Advance Pubertal Changes -- 9.5.3 Epidemiological Evidence for Alterations to Pubertal Timing -- 9.6 DISORDERS OF THE OVARY -- 9.6.1 Premature Ovarian Failure.
|
| 505 |
8 |
|
|a 9.6.2 Irregularity of Menstrual Cycles and Fecundity -- 9.6.3 Menopause -- 9.6.4 Polycystic Ovary Syndrome -- 9.7 UTERINE DISORDERS -- 9.7.1 Uterine Fibroids -- 9.7.2 Endometriosis -- 9.8 BENIGN BREAST DISEASE -- 9.9 FINAL COMMENTS -- References -- 10 -- Endocrine Disruption and Male Reproductive Health -- 10.1 INTRODUCTION -- 10.2 WHAT ARE THE ENDOCRINE TARGETS FOR DISRUPTION OF MALE REPRODUCTIVE HEALTH? -- 10.3 SOURCES AND TIMING OF ENDOCRINE DISRUPTION FOR MALE REPRODUCTIVE HEALTH -- 10.4 EXPOSURE TO DES IN UTERO AND FETAL ORIGIN OF ENDOCRINE DYSFUNCTION IN MEN -- 10.5 EXPOSURE TO EDCS IN ADULT LIFE AND GYNECOMASTIA -- 10.6 UROGENITAL TRACT MALFORMATIONS -- 10.6.1 Hypospadias and Cryptorchidism -- 10.6.2 Anogenital Distance -- 10.7 SPERM COUNTS AND SPERM QUALITY AS INDICATORS OF FERTILITY -- 10.8 TESTICULAR DYSGENESIS SYNDROME -- 10.9 PUBERTAL DEVELOPMENT -- 10.9.1 Physiological Changes in Puberty -- 10.9.2 Pubertal Timing and EDCs -- 10.10 PROSTATIC HYPERPLASIA -- 10.11 GENDER IDENTITY -- 10.12 FINAL COMMENTS -- References -- 11 -- Endocrine Disruption and Cancer of Reproductive Tissues -- 11.1 INTRODUCTION: HOW COULD ENDOCRINE DISRUPTION INFLUENCE CANCER DEVELOPMENT? -- 11.2 CANCERS IN FEMALE REPRODUCTIVE TISSUES -- 11.2.1 Breast Cancer -- 11.2.1.1 Case for Involvement of EDCs in the Rising Incidence of Breast Cancer -- 11.2.1.2 Exposure to Exogenous Estrogens and Breast Cancer -- 11.2.1.3 Measurement of EDCs in Human Breast Tissue -- 11.2.1.4 Functional Analysis of the Presence of EDCs in Human Breast Tissue -- 11.2.1.4.1 Animal Models -- 11.2.1.4.2 Epidemiological Studies -- 11.2.1.4.3 Disproportionate Incidence of Breast Cancer in the Upper Outer Quadrant of the Breast -- 11.2.1.4.4 Mechanisms of EDC Action in Cell Culture Models at Concentrations Measurable in Human Breast Tissue -- 11.2.1.4.4.1 Sustained Proliferation.
|
| 650 |
|
0 |
|a Endocrine disrupting chemicals.
|
| 650 |
|
0 |
|a Endocrine disrupting chemicals
|x Environmental aspects.
|
| 650 |
|
0 |
|a Endocrine disrupting chemicals
|x Health aspects.
|
| 650 |
|
2 |
|a Endocrine Disruptors
|0 (DNLM)D052244
|
| 650 |
|
6 |
|a Perturbateurs endocriniens.
|0 (CaQQLa)000268266
|
| 650 |
|
6 |
|a Perturbateurs endocriniens
|0 (CaQQLa)000268266
|x Aspect de l'environnement.
|0 (CaQQLa)201-0374355
|
| 650 |
|
7 |
|a Endocrine disrupting chemicals
|2 fast
|0 (OCoLC)fst01745376
|
| 700 |
1 |
|
|a Darbre, Philippa D.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Endocrine disruption and human health.
|b Second edition.
|d Amsterdam : Academic Press, 2021
|z 9780128219850
|w (OCoLC)1263792393
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128219850
|z Texto completo
|
